食管恶性黑色素瘤6例临床分析

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (585 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical features, diagnosis, treatment and prognosis of malignant melanoma of the esophagus. Methods Clinical data of 6 patients with malignant melanoma of the esophagus admitted to Peking University First Hospital from January 2013 to May 2017 were retrospectively analyzed and all patients were followed up. Results The average age of the 6 patients was 57.7 years old, 4 males and 2 females. There were 2 cases in the middle segment of the esophagus and 4 cases in the lower part of the esophagus. There were 2 cases misdiagnosed by endoscopic biopsy, and definite diagnosis need pathological section and immunohistochemistry method. All the 6 cases undertwent surgery, 1 case undertwent surgery alone, and 5 cases received postoperative adjuvant therapy. They were divided by postoperative pathological stage, 2 cases in stage Ⅰ, 3 cases in stage Ⅱ, and 1 case in stage Ⅲ. Among them, 1 case underwent resection of pulmonary metastases 21 months after operation, and the case was followed up for 60 months after operation. The survival time was 8 to 60 months, and the median survival time was 18 months. Conclusion Malignant melanoma of the esophagus is a rare and highly invasive malignant tumor. Early diagnosis and early treatment can improve the prognosis. Strictly selected PMME patients with isolated/localized, and removal of metastatic tumors has survival benefits. The progress of immune-targeted therapy can improve the prognosis of more patients, which is worthy of further study.

Key words： Esophagus Malignant melanoma Surgery Prognosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Qinghao LONG Zhiqiang HUANG Weiming SHANG Xueqian LI Jian

Cite this article:

LIU Qinghao LONG Zhiqiang HUANG Weiming SHANG Xueqian LI Jian. Clinical analysis of 6 cases of malignant melanoma of the esophagus[J]. 中国医药导报, 2018, 15(23): 109-112.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I23/109

[1] Gao S，Li J，Feng X，et al. Characteristics and surgical outcomes for primary malignant melanoma of the esophagus [J]. Sci Rep，2016，6：23804.
[2] Makuuchi H，Takubo K，Yanagisawa A，et al. Esophageal malignant melanoma：Analysis of 134 cases collected by the Japan Esophageal Society [J]. Esophagus，2015，12（2）：158-169.
[3] Bauer EH. Ein fall von primiarum melanoma des oesophagus [J]. ArbPathol Anat Inst Tubingen，1906，5：343-354.
[4] Garfinkle JM，Cahan WG. Primary melanocarcinoma of the esophagus；fist histologically proved case [J]. Cancer，1952， 5（5）：921-926.
[5] De La Pava S，Nigogosyan G，Pickem JW，et al. Melanosis of the esophagus [J]. Cancer，1963，16（1）：48-50.
[6] Tateishi R，Taniguchi H，Wada A，et al. Argyrophil cells and melanocytes in esophageal mucosa [J]. Arch Pathol，1974，98（2）：87-89.
[7] Ohashi K，Kato Y，Kanno J，et al. Melanocytes and melanosis of the oesophagus in Japanese subjects—analysis of factors effecting their increase [J]. Virchows Arch A Pathol Anat Histopathol，1990，417（2）：137-143.
[8] Iwanuma Y，Tomita N，Amano T，et al. Current status of primary malignant melanoma of the esophagus：clinical features， pathology， management and prognosis [J]. J Gastroenterol，2012，47（1）：21-28.
[9] 刘彦立，周志刚，闰会昌.原发性食管恶性黑色素瘤2例[J].放射学实践，2017，32（3）：302-304.
[10] Liu H，Yan Y，Jiang CM. Primary Malignant melanoma of the esophagus with unusual endoscopic findings：A case report and literature review [J]. Medicine（Baltimore），2016，95（17）：e3479.
[11] 刘肖琼，马钊，陈传贵，等.原发性食管恶性黑色素瘤的临床及预后分析[J].中华胃肠外科杂志，2016，19（1）：86-87.
[12] Zhao T，Kong FW，Wang H，et al. A long-term survivor with esophageal melanoma and pulmonary metastasis after single-stage esophagectomy and lobectomy [J]. Medicine （Baltimore），2017，96（21）：e7003.
[13] Nonoshita T，Shioyama Y，Nomoto S，et al. Effective palliative radiotherapy in primary malignant melanoma of the esophagus：a case report [J]. Cases J，2009，2：6928.
[14] 刘广杰，王滨，于哲，等.食管原发性恶性黑色素瘤17例临床特征和预后因素分析[J].中国全科医学，2015， 18（29）：3561-3565.
[15] Ho KY，Cheng J，Wee A，et al. Primary malignant melanoma of the esophagus with multiple esophageal lesions [J]. Nat Clin Pract Gastroenterol Hepatol，2007，4（3）：171-174.
[16] Sabanathan S，Eng J，Pradhan GN. Primary malignant melanoma of the esophagus [J]. Am J Gastroenterol，1989， 84（12）：1475-1481.
[17] 赵莉娟，邓辰亮，杨松林.恶性黑色素瘤靶向治疗的研究进展[J].中国美容整形外科杂志，2017，28（1）：57-59.
[18] Petrella T，Verma S，Spithoff K，et al. Adjuvant interferon therapy for patients at high risk for recurrent melanoma：an updated systematic review and practice guideline [J]. Clin Oncol（R Coll Radiol），2012，24（6）：413-423.
[19] Weber JS，K?覿hler KC，Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab [J]. J Clin Oncol，2012，30（21）：2691-2697.
[20] Ryder M，Callahan M，Postow MA，et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma：a comprehensive retrospective review from a single institution [J]. Endocr Relat Cancer，2014，21（2）：371-381.
[21] Long GV，Stroyakovskiy D，Gogas H，et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma：a multicentre，double-blind，phase 3 randomised controlled trial [J]. Lancet，2015， 386（9992）：444-451.
[22] Sasaki K，Uchikado Y，Omoto I，et al. Multidisciplinary therapy for metastatic primary malignant melanoma of the esophagus：A case report [J]. Mol Clin Oncol，2018，8（4）：533-538.
[23] Robert C，Long GV，Brady B，et al. Nivolumab in previously untreated melanoma without BRAF mutation [J]. N Engl J Med，2015，372（4）：320-330.
[24] Daud AI，Wolchok JD，Robert C，et al. Programmed death-ligand 1 expression in response to the anti-programmed death 1 antibody pembrolizumab in melanoma [J]. J Clin Oncol，2016，34（34）：4102-4109.
[25] Wolchok JD，Chiarion-Sileni V，Gonzalez R，et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma [J]. N Engl J Med，2017，377（14）：1345-1356.